The primary objective of the Biostatistics Core is to assist to the project investigators in the design, conduct, and analysis ofthe laboratory and clinical studies proposed in this program project grant (PPG). This core is led by Dr. Gary Rosner, Director of the Oncology Biostatistics and Bioinformatics Division. The Core focuses its efforts on assisting both the clinical and laboratory investigators in translating their pre-clinical studies into clinical studies by providing state-of-the-art experimental designs and analyses through statistical consultation and collaboration with respect to methodology, feasibility, safety monitoring, analysis, and reporting of clinical and laboratory studies. Additionally, Core members work closely with members of the Research Information Technology Systems (RITS) group, part of Oncology's Division of Biostatistics and Bioinformatics, to provide quality-controlled data in a systematic, efficient, and coordinated fashion so that accurate, complete, validated databases are available. This core has been and continues to be an integral part of the research accomplishments of the individual projects of this program project application

Public Health Relevance

(See Instructions): The work ofthe Biostatistics Core helps ensure that laboratory and clinical studies are carried out efficiently with designs that will lead to valid scientific conclusions. This work is a critical part ofthe research seeking to improve outcomes for cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA015396-38
Application #
8559502
Study Section
Special Emphasis Panel (ZCA1-RPRB-B)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
38
Fiscal Year
2013
Total Cost
$145,758
Indirect Cost
$55,784
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Schoch, Laura K; Cooke, Kenneth R; Wagner-Johnston, Nina D et al. (2018) Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2:2226-2229
Kasamon, Yvette L; Fuchs, Ephraim J; Zahurak, Marianna et al. (2018) Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. Biol Blood Marrow Transplant 24:1022-1028
Robinson, Tara M; Prince, Gabrielle T; Thoburn, Chris et al. (2018) Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients. Leuk Lymphoma 59:2801-2811
Grant, Melanie L; Bollard, Catherine M (2018) Cell therapies for hematological malignancies: don't forget non-gene-modified t cells! Blood Rev 32:203-224
Ghosh, Nilanjan; Ye, Xiaobu; Tsai, Hua-Ling et al. (2017) Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma. Biol Blood Marrow Transplant 23:1903-1909
Majzner, Robbie G; Mogri, Huzefa; Varadhan, Ravi et al. (2017) Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. Biol Blood Marrow Transplant 23:612-617
Alonso, Salvador; Jones, Richard J; Ghiaur, Gabriel (2017) Retinoic acid, CYP26, and drug resistance in the stem cell niche. Exp Hematol 54:17-25
Cruz, Conrad R Y; Bollard, Catherine M (2017) Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells. Curr Drug Targets 18:271-280
Fuchs, Ephraim Joseph (2017) Related haploidentical donors are a better choice than matched unrelated donors: Point. Blood Adv 1:397-400
Kanakry, Christopher G; BolaƱos-Meade, Javier; Kasamon, Yvette L et al. (2017) Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood 129:1389-1393

Showing the most recent 10 out of 456 publications